StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note published on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00. The firm has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Featured Articles
- Five stocks we like better than Genocea Biosciences
- What is Forex and How Does it Work?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is Put Option Volume?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.